The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Open accessAbstract
Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. The presence of 3 or more specific factors is indicative of metabolic syndrome, which is a significant influence upon future morbidity and mortality. We aimed to clarify the prevalence and predictors of metabolic syndrome (MetS) in adults with schizophrenia and related disorders, accounting for subgroup differences. A PRISMA systematic search, appraisal, and meta-analysis were conducted of 126 analyses in 77 publications (n = 25,692). The overall rate of MetS was 32.5% (95% CI = 30.1%-35.0%), and there were only minor differences according to the different definitions of MetS, treatment setting (inpatient vs outpatient), by country of origin and no appreciable difference between males and females. Older age had a modest influence on the rate of MetS (adjusted R(2) = .20; P < .0001), but the strongest influence was of illness duration (adjusted R(2) = .35; P < .0001). At a study level, waist size was most useful in predicting high rate of MetS with a sensitivity of 79.4% and a specificity of 78.8%. Sensitivity and specificity of high blood pressure, high triglycerides, high glucose and low high-density lipoprotein, and age (>38 y) are shown in supplementary appendix 2 online. Regarding prescribed antipsychotic medication, highest rates were seen in those prescribed clozapine (51.9%) and lowest rates of MetS in those who were unmedicated (20.2%). Present findings strongly support the notion that patients with schizophrenia should be considered a high-risk group. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
The Metabolic Syndrome and Cardiovascular Risk
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.034 · Cited by 3,009
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000380842.14048.7e · Cited by 1,600
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
A general cardiovascular risk profile: The Framingham study
Kannel, W. B., McGee, D., & Gordon, T. (1976) · The American Journal of Cardiology · doi:10.1016/0002-9149(76)90061-8 · Cited by 1,189
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 1×
“In recent years, it has become apparent that in patients with schizophrenia particular antipsychotic agents (AP) can have a negative impact on some of themodifiableMetS risk factors.(4,5) The differential effects of various AP on weight arewell described, with clozapine and olanzapine associated with the highest weigh…”
BackgroundDE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia
Ryan, M. C. M., Collins, P., & Thakore, J. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.284 · Cited by 828
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Self-citationPhysical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Self-citationFleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328
Self-citationPrevalence of Obesity and Metabolic Syndrome in Taiwan
Hwang, L.-C., Bai, C.-H., & Chen, C.-J. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60161-3 · Cited by 322
Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia
Spelman, L. M., Walsh, P. I., Sharifi, N., Collins, P., & Thakore, J. H. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02092.x · Cited by 318
Hanley, A. J. G., Karter, A. J., Williams, K., Festa, A., D’Agostino, R. B., Wagenknecht, L. E., & Haffner, S. M. (2005) · Circulation · doi:10.1161/circulationaha.105.559633 · Cited by 266
Álvarez-Jiménez, M., González-Blanch, C., Crespo-Facorro, B., Hetrick, S., Rodríguez-Sánchez, J. M., Pérez-Iglesias, R., & Vázquez-Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 264
De Hert, M., Schreurs, V., Sweers, K., Van Eyck, D., Hanssens, L., Šinko, S., Wampers, M., Scheen, A., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247
Self-citationThe metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 245
Metabolic profile of antipsychotic-naive individuals with non-affective psychosis
Fernandez-Egea, E., Bernardo, M., Donner, T., Conget, I., Parellada, E., Justicia, A., Esmatjes, E., Garcia-Rizo, C., & Kirkpatrick, B. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.052605 · Cited by 242
Tillin, T., Forouhi, N., Johnston, D. G., McKeigue, P. M., Chaturvedi, N., & Godsland, I. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1689-3 · Cited by 231
De Hert, M., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 217
Self-citationCorrell, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0408 · Cited by 216
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Capasso, R. M., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & St. Sauver, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.005 · Cited by 199
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 193
Bobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181
Diabetes mellitus and schizophrenia: Historical perspective
Kohen, D. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s64 · Cited by 181
Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study
Strassnig, M., Brar, J. S., & Ganguli, R. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007013 · Cited by 174
Wu, R., Zhao, J., Liu, Z., Zhai, J., Guo, X., Guo, W., & Tang, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0384-5 · Cited by 170
Vancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., & Binder, M. D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.03.011 · Cited by 157
Self-citationGraham, K. A., Perkins, D. O., Edwards, L. J., Barrier, R. C., Lieberman, J. A., & Harp, J. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.118 · Cited by 151
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis
Verma, S. K., Subramaniam, M., Liew, A., & Poon, L. Y. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04508 · Cited by 132
Mukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629.pub2 · Cited by 124
Choline, acetylcholine and dementia
Marchbanks, R. M. (1980) · Psychological Medicine · doi:10.1017/s0033291700039544 · Cited by 118
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 114
Physical health and schizophrenia
Mitchell, A. J., & Malone, D. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228767.71473.9e · Cited by 111
Self-citationCohn, T. A., Remington, G. J., Zipursky, R. B., Azad, A., Connolly, P., & Wolever, T. M. S. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100608 · Cited by 111
MTHFR and risk of metabolic syndrome in patients with schizophrenia
van Winkel, R., Rutten, B. P. F., Peerbooms, O., Peuskens, J., van Os, J., & Binder, M. D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.030 · Cited by 103
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population
Pérez‐Iglesias, R., Mata, I. F., Pelayo‐Terán, J. M., Amado, J., García‐Unzueta, M. T., Berja, A., Martínez‐García, O., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.028 · Cited by 102
Straker, D., Correll, C. U., Kramer‐Ginsberg, E., Abdulhamid, N., Koshy, F., Rubens, E. O., Saint-Vil, R., Kane, J. M., & Manu, P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1217 · Cited by 89
Vancampfort, D., Sweers, K., Probst, M., Maurissen, K., Knapen, J., Minguet, P., & Hert, M. A. F. D. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.12.007 · Cited by 80
Self-citationCardiometabolic effects of physical activity interventions for people with schizophrenia
Vancampfort, D., Knapen, J., Binder, M. D., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., Simons, J., & Probst, M. (2009) · Physical Therapy Reviews · doi:10.1179/108331909x12540993898053 · Cited by 79
Self-citationvan Winkel, R., Moons, T., Peerbooms, O., Rutten, B. P. F., Peuskens, J., Claes, S. J., van Os, J., & Binder, M. D. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833bc60d · Cited by 65
The metabolic syndrome and schizophrenia: A review
Meyer, J. M., Koro, C. E., & L'Italien, G. J. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071798 · Cited by 58
Oriot, P., Feys, J., de Wilmars, S. M., Misson, A., Ayache, L., Fagnart, O. C., Gruson, D., Luts, A., Jamart, J., Hermans, M. P., et al. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.03.003 · Cited by 55
Gaal, L. F. V. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.005 · Cited by 42
Tirupati, S., & Chua, L.-E. (2007) · Australasian Psychiatry · doi:10.1080/10398560701636906 · Cited by 30
Shi, L., Ascher‐Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V. A., & Winstead, D. K. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-80 · Cited by 28
Cohen, D., & Binder, M. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.94 · Cited by 27
Hert, M. D., Vancampfort, D., Correll, C. U., Peuskens, J., van Winkel, R., & Mitchell, A. J. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73892-5 · Cited by 8
Self-citation
Research works printed but not linked: 4
- Sengupta, 2005, Weight gain and lipid metabolic abnormalities induced by olanzapine first-episode, drug-naive patients with psychotic disorders, Schizophr Res, 80, 131, 10.1016/j.schres.2005.07.024 · DOI
- Szarek, 2009, Assessing metabolic syndrome: waist circumference versus BMI, Schizophr Res, 108, 295, 10.1016/j.schres.2008.12.003 · doi:10.1016/j.schres.2008.12.003
- Hodgson, 2004, Physical examination performed by psychiatrists, Int J Psychiatr Clin Pract, 8, 57, 10.1080/13651500310004830 · DOI
- De Hert, Antipsychotic medications metabolic, cardiovascular and cardiac risks [published online ahead of print October 18, 2011], Nat Rev Endocrinol
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationVancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Self-citationMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Metadata
- Authors
- Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-29
- Volume
- 39
- Issue
- 2
- Pages
- 306-318
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2168991266
- Cited by
- 1,082
- References
- 70
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.